RE:RE:AsksThe type A meeting will be just what the other poster said a meeting to determine a pathway going forward for MCNA. The result will most likely be that they will be required to run another phase 3 trial as it was mapped out with Endo years ago. The plan was always to have a second phase 3 trial going directly against BCG. When they partnered with Endo that was the plan until Endo changed the trial and decided to have MCNA go against Mitomycin C. This change in the trial resulted in low patient enrollemnt and the trial ended up being cancelled.
A little history here:
https://www.cantechletter.com/2014/07/investors-awaken-potential-newly-focused-bioniche-life-sciences/
This has been an long story and one thing to remember is that even Santa was able to get a deal done with a major US pharmaceutical. I believe a second phase 3 trial will be required and that they will end up partnering with a US pharmaceutical to run the trial.